Apex Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Apex Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$6.59M	Buy	195,877 +33,079	+20%	+$1.12M	0.15%	142
2015 Q4	$7.35M	Buy	162,798 +11,953	+8%	+$514K	0.16%	125
2015 Q3	$5.96M	Buy	150,845 +13,537	+10%	+$770K	0.13%	135
2015 Q2	$8.52M	Buy	137,308 +16,409	+14%	+$976K	0.18%	112
2015 Q1	$7.56M	Buy	120,899 +29,207	+32%	+$1.78M	0.18%	113
2014 Q4	$5.17M	Buy	+91,692	New	+$4.04M	0.14%	135

Other funds holding ANIP

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Apex Capital Management's ANIP Position: Q1 2016 in Review

Apex Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 20% in Q1 2016, buying an estimated $1.12M and bringing the position to 195,877 shares worth $6.59M. The position accounts for 0.15% of the portfolio, ranked #142.

Apex Capital Management first reported a position in ANIP in Q4 2014 and has held it in 6 quarters since. The position peaked at $8.52M in Q2 2015. 121 funds tracked by Wall St. Rank hold ANIP as of Q1 2016.

Apex Capital Management held 195,877 shares of ANI Pharmaceuticals worth $6.59M as of Q1 2016.
Apex Capital Management bought 33,079 ANI Pharmaceuticals shares in Q1 2016, an estimated $1.12M.
ANI Pharmaceuticals made up 0.15% of Apex Capital Management's portfolio in Q1 2016, its #142 holding.
Apex Capital Management first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 6 quarters since.
Apex Capital Management's ANI Pharmaceuticals position peaked at $8.52M in Q2 2015.
121 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.